In trials that compared 5 years of tamoxifen therapy to no endocrine therapy in patients with ER+ breast cancer, the recurrence rate in the tamoxifen group was approximately 50% lower during the first 5 years and approximately 30% lower during the subsequent 5 years. This evidence concerns the gene ESR1 and breast carcinoma.